Mesoblast limited Company Profile (NASDAQ:MESO)

About Mesoblast limited

Mesoblast limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MESO
  • CUSIP:
Key Metrics:
  • Previous Close: $6.40
  • 50 Day Moving Average: $6.08
  • 200 Day Moving Average: $5.11
  • 52-Week Range: $3.50 - $10.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.85
  • P/E Growth: 0.00
  • Market Cap: $483.61M
  • Outstanding Shares: 75,564,000
  • Beta: 2.89
Profitability:
  • Net Margins: -30.38%
  • Return on Equity: 5.87%
  • Return on Assets: 4.05%
Debt:
  • Current Ratio: 2.26%
  • Quick Ratio: 2.26%
Additional Links:
Companies Related to Mesoblast limited:

Analyst Ratings

Consensus Ratings for Mesoblast limited (NASDAQ:MESO) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $9.67 (51.04% upside)

Analysts' Ratings History for Mesoblast limited (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016Maxim GroupReiterated RatingBuy$14.00View Rating Details
6/14/2016Credit Suisse GroupDowngradeOutperform -> Neutral$10.00 -> $5.00View Rating Details
3/7/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$9.00 -> $10.00View Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldView Rating Details
11/24/2015Ladenburg Thalmann Financial ServicesReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Mesoblast limited (NASDAQ:MESO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2016Q216($0.06)$30.00 million$4.00 millionViewListenView Earnings Details
12/16/2015Q116($0.04)$7.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mesoblast limited (NASDAQ:MESO)
Current Year EPS Consensus Estimate: $-0.73 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividends

Dividend History for Mesoblast limited (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast limited (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Mesoblast limited (NASDAQ:MESO)
DateHeadline
einnews.com logoThousands of children and teenagers with anorexia forced to wait months for help (NASDAQ:MESO)
automotive.einnews.com - February 25 at 6:11 PM
einnews.com logoAttack on Syrian security forces in Homs kills 42 (NASDAQ:MESO)
world.einnews.com - February 25 at 6:11 PM
einnews.com logoPM warns of "fake news" peddled by parties bent on toppling gov't (NASDAQ:MESO)
semiconductors.einnews.com - February 25 at 6:11 PM
einnews.com logoUS seeks extradition of ex-Guatemalan vice president on drug charges (NASDAQ:MESO)
it.einnews.com - February 25 at 6:11 PM
einnews.com logoDPR attributes scarcity of petrol in Akwa Ibom to strike by tanker drivers (NASDAQ:MESO)
energy.einnews.com - February 25 at 6:11 PM
News IconVolatility Numbers in View for Mesoblast Limited (ASX:MSB) - Sherwood Daily (NASDAQ:MESO)
sherwooddaily.com - February 24 at 9:30 AM
News IconStock Focus: Watching the Levels for Mesoblast Limited (ASX:MSB) - Davidson Register (NASDAQ:MESO)
davidsonregister.com - February 23 at 7:07 AM
newsmaker.com.au logoStem Cell Therapy Market Would Register a Healthy Growth Rate During Forecast by 2020 (NASDAQ:MESO)
www.newsmaker.com.au - February 22 at 11:39 PM
openpr.com logoBone Marrow Transplant Market - Trend, Growth & Forecasts Research Report Upto 2022 (NASDAQ:MESO)
www.openpr.com - February 22 at 11:39 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Mesoblast limited (ADR) (NASDAQ:MESO) - Aiken Advocate (NASDAQ:MESO)
aikenadvocate.com - February 22 at 8:21 AM
News IconReviewing the Levels for Mesoblast Limited (ASX:MSB) - Midway Monitor (NASDAQ:MESO)
midwaymonitor.com - February 22 at 8:21 AM
News IconDurable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell ... - EconoTimes (NASDAQ:MESO)
www.econotimes.com - February 17 at 3:04 PM
News IconChecking the Charts on Shares of Mesoblast Limited (MSB.AX) - The Standard (NASDAQ:MESO)
6milestandard.com - February 17 at 3:04 PM
News IconDo Analysts See Any Upside to Mesoblast limited (ADR) (NASDAQ:MESO) Shares? - Rockville Register (NASDAQ:MESO)
rockvilleregister.com - February 17 at 3:04 PM
sbwire.com logoSolid Growth Ahead for Global Stem Cell Therapy Market by 2020 (NASDAQ:MESO)
www.sbwire.com - February 16 at 6:06 PM
finance.yahoo.com logoDurable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents (NASDAQ:MESO)
finance.yahoo.com - February 16 at 6:06 PM
finance.yahoo.com logo4:56 pm Mesoblast announces 39-week date from its Phase 2 trial in patients with rheumatoid arthritis resistant to anti-Tumor Necrosis Factor agents (NASDAQ:MESO)
finance.yahoo.com - February 16 at 6:06 PM
openpr.com logoBone Marrow Transplant Market Revenue, Opportunity, Forecast and Value Chain 2016-2026 (NASDAQ:MESO)
www.openpr.com - February 14 at 12:41 AM
4-traders.com logoMesoblast : Published Results Show MSB Cells Effective In RA Model (NASDAQ:MESO)
www.4-traders.com - February 14 at 12:41 AM
News IconStem cell therapy market forecasts impressive growth by 2022 according to new research report (NASDAQ:MESO)
www.whatech.com - February 10 at 5:35 AM
4-traders.com logoMesoblast : Release of shares from voluntary escrow (NASDAQ:MESO)
www.4-traders.com - February 10 at 5:35 AM
News IconGood Growth Opportunities in Global Bone Marrow Transplant Market Till 2026 (NASDAQ:MESO)
reports.pr-inside.com - February 9 at 12:22 AM
live-pr.com logoNew Study: Degenerative Spondylolisthesis Global Clinical Trials Review, H2, 2016 (NASDAQ:MESO)
www.live-pr.com - February 3 at 7:14 PM
openpr.com logoGlobal Regenerative Therapies Market to Raise at a CAGR of 20.0% During the Forecast Period 2016 - 2022 (NASDAQ:MESO)
www.openpr.com - February 3 at 1:29 AM
News IconMesoblast Director Recognized by Peers for Cardiovascular Leadership - irasia.com (press release) (NASDAQ:MESO)
www.irasia.com - February 1 at 5:25 AM
finance.yahoo.com logoMesoblast Director Recognized by Peers for Cardiovascular Leadership (NASDAQ:MESO)
finance.yahoo.com - January 31 at 7:24 PM
News IconMesoblast Limited MSB Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:MESO)
www.bioportfolio.com - January 28 at 6:37 PM
News IconTechnical Level Spotcheck on Shares of Mesoblast Limited (MSB.AX) - Market Point (NASDAQ:MESO)
mtptnews.com - January 26 at 9:23 PM
News IconStem Cell Therapy Market Size, Share, Analysis, Report and Forecast to 2022" (NASDAQ:MESO)
www.prlog.org - January 24 at 7:13 PM
News IconStem Cell Therapy Market Explores New Growth Opportunities By 2020 (NASDAQ:MESO)
www.medgadget.com - January 24 at 7:13 PM
News IconStock Perspective: Mesoblast limited (ADR) (NASDAQ:MESO) Earnings in View - Aiken Advocate (NASDAQ:MESO)
aikenadvocate.com - January 23 at 11:49 PM
News IconGraft Versus Host Disease GvHD Treatment Market Forecast By End-use Industry 2016-2026 (NASDAQ:MESO)
reports.pr-inside.com - January 20 at 7:18 PM
News IconMesoblast Limited (NASDAQ:MESO) Valuation According To ... - UK Market News (NASDAQ:MESO)
www.ukmarketnews.co.uk - January 20 at 1:31 AM
News IconBone Marrow Transplant Market Revenue and Value Chain 2016-2026 (NASDAQ:MESO)
reports.pr-inside.com - January 19 at 5:08 AM
fool.com logoIs it time to pile into Sirtex Medical Limited? - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - January 17 at 11:54 PM
News IconEarnings According to Analysts for Mesoblast limited (ADR) (NASDAQ:MESO)? - Aiken Advocate (NASDAQ:MESO)
aikenadvocate.com - January 17 at 11:54 PM
News IconBrain Iron May Predict Progression in Alzheimer's (NASDAQ:MESO)
www.medscape.com - January 17 at 6:53 PM
News IconGlobal Regenerative Therapies Market to Approach US$ 18,429.8 Million by 2022 (NASDAQ:MESO)
www.medgadget.com - January 14 at 6:35 PM
4-traders.com logoMesoblast limited : Blog Coverage Mesoblast Receives Payment from Mallinckrodt (NASDAQ:MESO)
www.4-traders.com - January 13 at 7:49 PM
finance.yahoo.com logoBlog Coverage Mesoblast Receives Payment from Mallinckrodt (NASDAQ:MESO)
finance.yahoo.com - January 13 at 7:49 PM
4-traders.com logoMesoblast : MSB Presentation To Annual J.P.Morgan Healthcare Conference (NASDAQ:MESO)
www.4-traders.com - January 13 at 12:04 AM
fool.com logoWhy the Mesoblast limited share price is taking off (NASDAQ:MESO)
www.fool.com.au - January 13 at 12:04 AM
fool.com logoASX 200 ends lower: 12 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - January 12 at 5:08 AM
News IconMesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference - irasia.com (press release) (NASDAQ:MESO)
www.irasia.com - January 12 at 5:08 AM
streetinsider.com logoMesoblast Limited (MESO) Issues 20.04M Shares to Mallinckrodt (MNK) - StreetInsider.com (NASDAQ:MESO)
www.streetinsider.com - January 10 at 6:41 AM
News IconMesoblast Ltd MSB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MESO)
www.bioportfolio.com - January 10 at 12:14 AM
sbwire.com logoRegenerative Therapies Market Will Reach US $18,429.8 Million by 2022 (NASDAQ:MESO)
www.sbwire.com - January 9 at 7:13 PM
News IconBone Marrow Transplant Market by Product & Data Validation, Analysis and Forecast 2022 (NASDAQ:MESO)
empowerednews.net - January 9 at 7:13 PM
einnews.com logoKazakhstan keeps rate at 12 pct, hints at more rate cuts (NASDAQ:MESO)
world.einnews.com - January 9 at 7:13 PM
streetinsider.com logoMesoblast Limited (MESO) Issues 20.04M Shares to Mallinckrodt (MNK) (NASDAQ:MESO)
www.streetinsider.com - January 9 at 7:13 PM

Social

What is Mesoblast limited's stock symbol?

Mesoblast limited trades on the NASDAQ under the ticker symbol "MESO."

Where is Mesoblast limited's stock going? Where will Mesoblast limited's stock price be in 2017?

4 equities research analysts have issued 12 month price targets for Mesoblast limited's shares. Their predictions range from $5.00 to $14.00. On average, they anticipate Mesoblast limited's share price to reach $9.67 in the next year.

Who owns Mesoblast limited stock?

Mesoblast limited's stock is owned by many different of institutional and retail investors. Top institutional investors include Prudential PLC (2.03%), Commerzbank Aktiengesellschaft FI (0.03%) and Osborn Williams & Donohoe LLC (0.03%).

Who sold Mesoblast limited stock? Who is selling Mesoblast limited stock?

Mesoblast limited's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC.

Who bought Mesoblast limited stock? Who is buying Mesoblast limited stock?

Mesoblast limited's stock was purchased by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI.

How do I buy Mesoblast limited stock?

Shares of Mesoblast limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mesoblast limited stock cost?

One share of Mesoblast limited stock can currently be purchased for approximately $6.40.

Mesoblast limited (NASDAQ:MESO) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Mesoblast limited (NASDAQ:MESO)

Earnings History Chart

Earnings by Quarter for Mesoblast limited (NASDAQ:MESO)

Dividend History Chart

Dividend Payments by Quarter for Mesoblast limited (NASDAQ:MESO)

Last Updated on 2/25/2017 by MarketBeat.com Staff